This clinical trial is focused on studying a condition known as sepsis-associated acute kidney injury (SA-AKI). Sepsis is a serious condition that occurs when the body has an extreme response to an infection, which can lead to damage in various organs, including the kidneys. In this study, researchers are investigating a new treatment called TIN816, which is a powder that is mixed into a solution and given to patients through an injection or infusion into a vein. The purpose of the study is to explore how different doses of TIN816 affect kidney function in patients with SA-AKI.

Participants in the study will be randomly assigned to receive either TIN816 or a placebo, which is a solution that does not contain the active drug. The study will be conducted in a way that neither the participants nor the researchers know who is receiving TIN816 or the placebo, to ensure unbiased results. The study will last for several weeks, during which time participants will receive the treatment and have their kidney function monitored through various tests. These tests will help determine how well the kidneys are working by measuring substances like creatinine, which is a waste product filtered by the kidneys.

The study aims to gather information on the safety and effectiveness of TIN816 in improving kidney function in patients with SA-AKI. Researchers will also look at other important outcomes, such as the occurrence of any serious kidney-related events and overall health status over a period of time. The results of this study could provide valuable insights into new treatment options for patients suffering from this serious condition.